The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC)

Cell Mol Immunol. 2012 Mar;9(2):103-4. doi: 10.1038/cmi.2011.43. Epub 2011 Oct 10.

Authors

Lifeng Wang¹, Zheng Zhang, Fu-Sheng Wang

Affiliation

¹ Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China.

No abstract available

Publication types

Review

MeSH terms

Animals
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism*
Carcinoma, Hepatocellular / diagnosis*
Carcinoma, Hepatocellular / genetics
Carcinoma, Hepatocellular / pathology
Carcinoma, Hepatocellular / physiopathology
Cell Transformation, Neoplastic* / genetics
Disease Progression
Down-Regulation
Genetic Therapy
Humans
Lipid Metabolism / genetics
Liver Neoplasms / diagnosis*
Liver Neoplasms / pathology
Liver Neoplasms / physiopathology
MicroRNAs / genetics
MicroRNAs / metabolism*
Organ Specificity
Pathology, Molecular / trends
Predictive Value of Tests
Prognosis

Substances

Biomarkers, Tumor
MIRN122 microRNA, human
MicroRNAs